Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

NRIXNRIX
Showing 8 of 24 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in NURIX THERAPEUTICS INC

CITADEL ADVISORS LLC holds 1.5M shares of NRIX (NURIX THERAPEUTICS INC), worth $35.8M as of 2026-Q2. The position was increased (+9.9% shares). NRIX represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$35.8M

Current Shares

1.5M

Total Value Change

+$1.4M

Total Shares Change

-54,186

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
1.5M
+9.9%
$35.8M0.0%$24.26
32
2026-Q1
Increased
1.3M
+16.6%
$20.8M0.0%$15.81
33
2025-Q4
Increased
1.2M
+104.0%
$21.9M0.0%$19.02
46
2025-Q3
Decreased
565,305
-64.4%
$5.2M0.0%$9.28
0
2025-Q2
Increased
1.6M
+20.6%
$18.1M0.0%$11.64
34
2025-Q1
Increased
1.3M
+54.7%
$15.7M0.0%$12.15
40
2024-Q4
Decreased
851,519
-44.4%
$16M0.0%$18.64
0
2024-Q3
Increased
1.5M
+47.1%
$34.4M0.0%$23.05
40

Other major holders of NRIX: BlackRock, Inc., FMR LLC, BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used